Genentech, Inc.
NEWS
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
The FDA accepted Genentech’s New Drug Application (NDA) for baloxavir marboxil, a single-dose, oral flu treatment for people 12 years and older. It also granted it Priority Review.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
From CRISPR to spider silk there are some great scientific research stories out this week.
The U.S. Food and Drug Administration (FDA) approved Genentech’s Rituxan (rituximab) to treat adults with moderate to severe pemphigus vulgaris (PV).
The Biocom Institute and California Life Sciences Institute (CLSI) released their third biennial life science industry report. Overall, the report paints a very positive picture of the life science industry in California.
Genentech, a Roche company, and Microbiotica signed a multi-year strategic collaboration to discover, develop and commercialize biomarkers, targets and drugs for inflammatory bowel disease (IBD).
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
JOBS
IN THE PRESS